Search

Purpose: [ABSTRACT FROM AUTHOR]

Purpose To compare the diagnostic accuracy of contrast-enhanced ultrasonography (CE-US), contrast-enhanced CT (CE-CT), and superparamagnetic iron oxide-enhanced MRI (SPIO-MRI) with diffusion-weighted imaging (DWI) in the evaluation of colorectal hepatic metastases. Materials and Methods Thirty-six patients with colorectal cancers were prospectively enrolled and retrospectively evaluated. Of the 86 metastases identified, 16 were confirmed histologically and the remaining 70 were confirmed by follow-up imaging. CE-CT and SPIO-MRI + DWI were independently evaluated by two readers, whereas CE-US was evaluated by consensus reading of two different readers. Area under receiver operating characteristic curve (Az), sensitivities, and positive predictive values (PPVs) were calculated and compared. Results For both readers, SPIO-MRI+DWI had significantly greater Az (0.879 and 0.904) and sensitivity (78% and 87%) for all lesions compared with CE-CT (0.779 and 0.793; 59% and 59%) and CE-US (0.811; 69%), and significantly greater Az (0.783 and 0.837) and sensitivity (56% and 73%) for lesions ≤1 cm compared with CE-CT (0.562 and 0.601; 20% and 22%) and CE-US (0.66; 37%). For lesions >1 cm, there was no significant difference in Az, sensitivity and PPV between all the image sets. Conclusion SPIO-MRI with DWI was the most reliable modality for evaluation of liver metastases particularly for lesions ≤1 cm. J. Magn. Reson. Imaging 2010;32:1132-1140. © 2010 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]

Purpose: To clarify the factors that predict enhancement of the liver parenchyma in hepatocyte-phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging. Materials and Methods: Gd-EOB-DTPA-enhanced hepatocyte-phase MR images of 198 patients with chronic liver diseases (Child-Pugh class A in 112 patients, class B in 74 patients, and class C in 12 patients) were retrospectively analyzed. The hepatocyte-phase images were obtained using fat-suppressed T1-weighted gradient-echo images with a 3D acquisition sequence 10 min and 20 min after IV administration of Gd-EOB-DTPA (0.025 mmol/kg body weight). The quantitative liver-spleen contrast ratio (Q-LSC) was calculated using the signal intensities of the liver and spleen. Serum albumin levels, total bilirubin levels, prothrombin activity, and the results of indocyanine green clearance tests (ICGs) were recorded and correlated with the Q-LSC. Logistic regression analysis was performed to analyze which factors predict sufficient liver enhancement using a Q-LSC of 1.5 as a cutoff value. Results: Only ICGs and Child-Pugh classifications showed a statistically significant correlation with the Q-LSC. Logistic regression analysis showed that ICGs were the only factors that accurately predicted liver enhancement on hepatocyte-phase images. Conclusion: ICGs were found to be predictors of sufficient liver enhancement on hepatocyte-phase images. J. Magn. Reson. Imaging 2009;30:1042-1046. © 2009 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]

Purpose: To evaluate the effectiveness of diffusion-weighted magnetic resonance imaging (DWI) in estimating the grade of malignancy of hepatocellular carcinoma. Materials and Methods: Dynamic contrast-enhanced computed tomography (CE-CT) and DWI (b value, 1000 s/mm2) were performed on 73 patients. Using DW images, the lesions were classified as 'visible' or 'invisible.' The apparent diffusion coefficient (ADC) of the lesions was measured. Furthermore, the lesions were classified as hypervascular or iso-hypovascular using arterial phase CE-CT images. The image findings for each lesion type were compared. Results: The 73 patients had 98 hepatocellular lesions, of which 12 were histologically diagnosed as dysplastic nodules; 39, well-differentiated HCCs; 33, moderately differentiated HCCs; and 14, poorly differentiated HCCs. The mean ADC values of moderately poorly-differentiated HCCs were significantly lower than well-differentiated HCCs and dysplastic nodules ( P < 0.01). On DW images, >90% of moderately (30/33) and poorly differentiated HCCs (13/14) were visible, while 51% of well-differentiated HCCs (20/39) and all dysplastic nodules were invisible. Of 22 iso-hypovascular lesions, 4 were visible on DW images and were poorly differentiated HCCs, whereas 18 were invisible and were dysplastic nodules (12/18) or well-differentiated HCCs (6/18). Conclusion: A combination of hypovascularity and visibility on DW images can help distinguish poorly differentiated HCCs from low-grade hepatocellular lesions (dysplastic nodules and well-differentiated HCCs). J. Magn. Reson. Imaging 2009;30:1005-1011. © 2009 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]

Recurrence of hepatocellular carcinoma (HCC) is frequently observed in patients with hepatitis C virus (HCV) infection and the incidence of HCC recurrence is as high as 20% in these patients even after a complete curative treatment is given for the HCC nodules. We report a 57-year-old female who was referred to our hospital for the treatment of a HCC nodule of 1.8 cm diameter in S5 and having liver cirrhosis of Child–Pugh A classification with HCV infection in April 1999. The HCC nodule showed hypervascularity by computed tomography during hepatic arteriography (CTHA) and was coagulated by microwave under peritoneoscopy. Complete necrosis was confirmed by enhanced-CT scan after microwave coagulation. Thereafter, interferon alfa-2b (3MU, twice weekly) was given but HCV RNA continued to be positive. Thereafter, recurrence of HCC was noted five times in S1, S2, S6; treatment by radiofrequency ablation was given four times; and transarterial chemoembolization was carried out once. Since January 2004, peg-interferon alfa-2a (90 µm/week) has been administered, and no recurrence has been detected until August 2005. She is currently 63 years old, and quite well. Five-year-survival rate in HCC patients treated by radiofrequency ablation is 62.7% in our hospital, however, the recurrence rate is as high as 26.4% per year in the patients with chronic HCV infection. It is a point of controversy when liver transplantation should be recommended in HCC patients with liver cirrhosis of Child-Pugh A classification having chronic HCV infection because of the high incidence of recurrence. [ABSTRACT FROM AUTHOR]

Abstract: The up-regulation of MUC1 protein is associated with malignant phenotype of cancer. We investigated the significance of KL-6, one of the MUC1 antigens, as a tumor marker in hepatitis C virus positive hepatocellular carcinoma (HCC). Serum KL-6 was determined in 203 patients with chronic hepatitis (CH), 47 patients with liver cirrhosis (LC) and 78 patients with HCC. KL-6 was higher in HCC compared to non-HCC (p =0.0005) and was higher in patients with multiple HCC nodules compared to a single nodule (p =0.02). There was no correlation between KL-6 and existent tumor markers for HCC such as alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein or des-gamma-carboxyprothrombin. In the prospective analysis, the cumulative incidence of HCC was significantly greater in CH and LC patients with high initial KL-6 (above 400U/ml) compared to the others (p =0.02). Moreover, in the prospective observation of 25 patients whose HCC was completely cured by radiofrequency ablation therapy, the cumulative incidence of distant recurrences was significantly greater in patients with high initial KL-6 compared to the others (p =0.005). These results suggest that serum KL-6 could be a novel tumor marker in the diagnosis and the prediction of prognosis of HCC that may have additive value to the existent markers. [Copyright &y& Elsevier]

During the follow-up of 19 patients with self-limited acute hepatitis B for more than 2 years, clearance of hepatitis B surface antigen from the sera was observed in all patients within 6 months after disease onset, and the corresponding antibody (anti-HBs) appeared in 17 of the 19 patients within 12 months. However, upon performing nested polymerase chain reaction with the estimated sensitivity of 120–200 copies/ml, using two independent pairs of primers derived from the well-conserved sequences in the S gene or C gene region of the hepatitis B virus (HBV) genomes of all seven genotypes, HBV DNA was detected over a period of at least 12 months in serum samples obtained from five (26%) of the 19 patients, although it became undetectable in all five patients at 2–3 years after disease onset. The titer of antibody against hepatitis B core antigen (anti-HBc), assayed by the hemagglutination inhibition (HI, 2N) test, was significantly lower at the initial examination in the five patients who remained viremic for at least 12 months, than in the remaining 14 patients who cleared HBV DNA from their sera within 12 months after disease onset (10.6±2.7 vs. 13.6±0.7, P<0.02). Furthermore, these five patients showed a significantly lower rate of decrease of anti-HBc titer during the 12-month period after disease onset than the remaining 14 patients (55.0±32.6 vs. 91.0±7.9%, P<0.01). These results indicate that the initial titer and dynamics of anti-HBc may reflect the evolution of HBV viremia after clinical recovery from acute hepatitis B. [Copyright &y& Elsevier]